Study on RSV Infection Prevention in Infants in France Comparing Maternal Vaccination During Pregnancy and Newborn Immunization

What this Trial Is About

Bronchiolitis is a viral infection affecting the lower respiratory tract, most often caused by the respiratory syncytial virus RSV. It is a leading cause of infant hospitalizations for respiratory distress in Europe, with a significant impact on healthcare resources and families. This study focuses on understanding how pregnant women in France adhere to the current prevention strategies for RSV infections in infants, which have recently evolved with new options becoming available. The prevention strategies evaluated include maternal vaccination with the RSV vaccine Abrysvo during the third trimester of pregnancy and direct immunization of neonates with the monoclonal antibody nirsevimab. The maternal vaccine aims to transfer antibodies to the infant before birth, while nirsevimab is given as a single dose to neonates during their first RSV season. These strategies complement traditional non-pharmacological measures and are part of the national prevention program between September 2024 and January 2025. Participants in this observational study will complete an online questionnaire about 10 minutes long, which collects information about their choices regarding RSV prevention, factors influencing these choices, and reasons for adherence or non-adherence. The study will track adherence and related factors over six months, providing insights into maternal decision-making. The goal is to better understand how these prevention options are accepted and applied in the general population to inform future public health efforts.

Prevention Strategy for Respiratory Syncytial Virus (RSV) Infections in Infants in France